Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update.

Konstan MW, Ramsey ML, Sathe M, Freeman AJ, Freedman SD, Schwarzenberg SJ, O'Rourke C, Onchiri FM, Setiawan L, Pilewski JM, Mayer-Hamblett N

Open source

DOI
10.1016/j.clinthera.2026.04.021
Published
2026 Jul
Container
Clinical therapeutics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clinthera.2026.04.021,
  title = {Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update.},
  author = {Konstan MW and Ramsey ML and Sathe M and Freeman AJ and Freedman SD and Schwarzenberg SJ and O'Rourke C and Onchiri FM and Setiawan L and Pilewski JM and Mayer-Hamblett N},
  year = {2026},
  journal = {Clinical therapeutics},
  doi = {10.1016/j.clinthera.2026.04.021},
  url = {https://doi.org/10.1016/j.clinthera.2026.04.021}
}

RIS

TY  - JOUR
TI  - Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update.
AU  - Konstan MW
AU  - Ramsey ML
AU  - Sathe M
AU  - Freeman AJ
AU  - Freedman SD
AU  - Schwarzenberg SJ
AU  - O'Rourke C
AU  - Onchiri FM
AU  - Setiawan L
AU  - Pilewski JM
AU  - Mayer-Hamblett N
PY  - 2026
JO  - Clinical therapeutics
DO  - 10.1016/j.clinthera.2026.04.021
UR  - https://doi.org/10.1016/j.clinthera.2026.04.021
ER  - 

APA

MW, K., ML, R., M, S., AJ, F., SD, F., SJ, S., C, O., FM, O., L, S., JM, P., & N, M. (2026). Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update.. Clinical therapeutics. https://doi.org/10.1016/j.clinthera.2026.04.021

Source records